Press Release

CELLiST helps stabilize the domestic supply of cell culture media, which was entirely dependent on imports

Improved production and efficiency by applying ‘switch program’

Domestic bio companies are showing rapid growth by continuing the Korean Wave craze with ‘K-Bio’ in the wake of 

the COVID-19 incident. Meanwhile, Ajinomoto Genexine, a bio-process raw material manufacturing and research company, is 

targeting the domestic and global markets with its cell culture medium product brand CELLiST.

Ajinomoto Genexine is a joint venture between Genexine, a domestic bio venture company, and Ajinomoto, a global food and 

amino acid supplier. By combining the know-how of 'Ajinomoto', which leads the market for amino acids, the main raw material 

for cell culture media, and 'Genexine', which is recognized for its technology in the field of biopharmaceutical development, we 

are contributing to the growth of K-Bio by developing and manufacturing cell culture media domestically. I'm doing it.

Cell culture medium is a mixture of nutrients necessary for cell culture and is an essential raw material in the biopharmaceutical 

field. For the development of biopharmaceuticals, cell culture is the basis for all processes from research and development to 

production, so cell culture media, an essential element in cell culture, is the most important element. However, the media used in the production of bio and pharmaceutical products used domestically have been entirely dependent on overseas imports.

Accordingly, Ajinomoto Genexine settled in Songdo, Incheon in 2012 and introduced the cell culture medium product brand 

‘CELLiST’. CELLiST has been developing and manufacturing animal cell culture media and providing media consignment production services based on Ajinomoto's media manufacturing technology and know-how, which has been conducting serum-free media 

research for over 30 years.

CELLiST manufactures media at its domestic factories to secure supply stability and price competitiveness and supports the 

acceleration of domestic biopharmaceutical development. As a result of supplying highly satisfactory solutions based on 

cutting-edge technology in line with the growth of Korea's biopharmaceutical market, the company has established itself as a 

company contributing to the development of high-quality, high-value-added drugs.

The secret to CELLiST's remarkable growth in a relatively short period of time lies in differentiated services through the operation of the ‘Switch Program’. By changing the cell culture medium (media switch), which is a major element of the biopharmaceutical production process, we have provided customers with effects such as increased productivity, improved antibody quality, and cost reduction.

According to CELLiST's explanation, product development is possible in as little as 3 to 6 months. In addition, in addition to 

supporting experiments with devices such as ambr and HPLC, services such as equivalence test support, documentation filing, 

and response to licensing agencies are also in progress.

An official from Ajinomoto Genexine said, “In order to gain an upper hand in the fierce biopharmaceutical market, cost reduction and securing productivity are the keys.” He added, “We are using the media through the switch program of CELLiST, which has 

experience in changing cell culture medium in numerous biosimilar and new drug pipelines at home and abroad. “If you proceed with the change, you can easily change the medium at any stage to increase biopharmaceutical development and production 

efficiency.”